SBTX: Silverback Therapeutics, Inc. - Summary | Jitta

Silverback Therapeutics, Inc.

NASDAQ:SBTX

Notice
Stock data is unavailable or the company’s delisted.
Price
$5.87
Loss Chance
58.4%
0.08JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (2)
Recent Business Performance (19)
Financial Strength (22)
Return to Shareholders (0)
Competitive Advantage (1)
Jitta Signs
SG&A to SalesDecreasing Every Year
Cash Conversion CycleLess than 30 days
Recent IPOLess than 3 years
Recent Business PerformanceEarning decline 129.25% in the last year
SG&A to SalesIncreasing Every Year
Key Stats
Jitta Score
Jitta Line
0.08
100.00%
2.43
422.26%
2.43
422.26%
4.41
53.66%
3.32
38.04%
2.67
16.43%
COMPANY DESCRIPTION
As of November 8, 2022, Silverback Therapeutics, Inc. was acquired by ARS Pharmaceuticals, Inc., in a reverse merger transaction. Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.